Phosphorylated PLCγ1 (Tyr783): Regulating Liquid‑Liquid Phase Separation Within T‑Cell Receptor Signalling Cascades

LAT‑Driven Liquid‑Liquid Phase Separation as Core Organizing Principle for Immune‑Receptor Signalling

Upon antigen‑triggered activation, immune‑cell receptors including TCR, BCR and CAR drive dynamic self‑assembly of nanometer‑to‑micrometre‑sized signal‑enriched microclusters on plasma‑membrane surfaces. These mesoscale assemblies constitute central signalling hubs that shape overall immune‑response magnitude and antigen‑response specificity.

Accumulated mechanistic evidence identifies liquid‑liquid phase separation (LLPS) as the key biophysical principle governing such sub‑cellular condensate formation. In T‑lymphocytes, phosphorylated linker‑for‑activation‑of‑T‑cells (LAT) undergoes phase separation to recruit downstream signalling components and amplify TCR‑originated signal flows. Nevertheless, critical mechanistic gaps remain, concerning how LAT‑mediated LLPS receives fine‑tuned modulation and what functional contributions other signal‑transduction proteins deliver within these condensates.

Canonical Catalytic versus Non‑Canonical Scaffolding Functions of PLCγ1 in TCR Signal Transduction

Phospholipase‑C‑gamma 1 (PLCγ1) represents a well‑characterized effector molecule downstream of activated LAT complexes within T‑cell‑receptor signalling cascades. Its canonical enzymatic function takes place following membrane recruitment to phosphorylated LAT. Activated PLCγ1 hydrolyses phosphatidylinositol‑4,5‑bisphosphate (PIP2) to generate IP3 and DAG second messengers, initiating calcium‑influx events and PKC‑dependent signalling branches essential for full T‑cell‑activation programmes.

Recent mechanistic investigations uncovered a separate enzymatic‑activity‑independent scaffolding role for PLCγ1. This polypeptide substantially stabilizes LAT‑derived phase‑separated microclusters via modular domain‑mediated intermolecular contacts. PLCγ1 possesses tandem SH2 domains plus one SH3 domain, granting intrinsic multivalent cross‑linking capacity that shapes condensate architecture independent of phospholipase catalytic turnover.

Multi‑Modal Mechanisms by Which PLCγ1 Modulates LAT Liquid‑Liquid Phase Separation

PLCγ1 exerts regulatory influence over LAT‑LLPS through three distinct mechanistic modes. First, its two SH2 domains simultaneously engage multiple phosphorylated LAT polypeptide chains, acting as a molecular cross‑linker. Multivalent binding drives local LAT‑molecule concentration elevation and reinforces phase‑separated condensate structures against uncontrolled diffusion or premature disassembly.

Second, PLCγ1 binding confers partial shielding effect against plasma‑membrane‑resident CD45 tyrosine‑phosphatase activity. Physical steric hindrance or local conformational alteration protects critical phospho‑tyrosine residues on LAT from rapid de‑phosphorylation. Sustained LAT phosphorylation preserves its competence for continued phase‑separation behaviour and downstream signal‑propagation.

Third, PLCγ1 exhibits non‑monotonic, concentration‑dependent regulatory characteristics. Moderate physiological‑relevant concentrations promote robust LAT‑condensate assembly. Excessively high PLCγ1 concentrations instead suppress large‑scale aggregate formation. Computational patchy‑particle‑simulation models explain this observation: surplus PLCγ1 occupies available binding interfaces and functions as network‑terminating nodes without expanding inter‑molecular cross‑links, restricting further growth of phase‑separated assemblies.

Research Value of Phospho‑PLCγ1 (Tyr783) Site‑Specific Immunodetection Reagents

PLCγ1 activation status is tightly controlled via tyrosine‑residue phosphorylation events triggered by upstream Src‑family kinases during T‑cell stimulation. Among these modification sites, Tyr783 phosphorylation serves as a reliable biochemical marker reflecting full PLCγ1 functional activation.

Site‑specific Phospho‑PLCγ1 (Tyr783) recombinant rabbit monoclonal antibody delivers multiple investigative benefits for LLPS‑focused immunology‑basic‑research. Time‑course immunoblot measurements document the amplitude and temporal kinetics of Tyr783 phosphorylation after TCR triggering. Researchers may thereby temporally correlate PLCγ1 catalytic‑activation windows against LLPS‑scaffold‑driven phase‑separation functional periods. Immunofluorescence imaging co‑localizes p‑Tyr783‑PLCγ1 signal with LAT‑positive condensates, spatially connecting kinase‑activation status to phase‑separated signalling‑platform compartments. This antibody also supports epistasis‑oriented mechanistic studies of kinases‑phosphatases governing PLCγ1 modification and resultant LAT‑LLPS output changes. Furthermore, it furnishes a pharmacodynamic read‑out for evaluating TCR‑pathway responses under immunomodulatory‑compound or CAR‑T‑optimization‑related experimental‑conditions.

Broader Conceptual Implications for Diverse Receptor‑Signalling Research

PLCγ1 participates in signal‑transduction cascades initiated by BCR, Fc‑receptor and multiple growth‑factor‑receptor families beyond TCR signalling. Its functional dysregulation correlates with immunodeficiency, autoimmune pathology and oncogenic cellular phenotypes in various pre‑clinical‑model‑systems.

The newly‑discovered non‑canonical LLPS‑scaffold activity raises open investigative questions. One key research direction explores whether PLCγ1 employs analogous multivalent cross‑linking logic to modulate phase‑separated condensate assembly downstream of other receptor classes. Such mechanistic insights inspire alternative therapeutic‑candidate design strategies, targeting SH2‑domain‑mediated protein‑protein‑interaction surfaces rather than solely inhibiting the phospholipase catalytic pocket. Reliable phospho‑site‑specific antibody tools remain indispensable for tracking PLCγ1 activation dynamics across these diverse experimental‑model‑systems.

Phospho‑PLCγ1 (Tyr783) Recombinant Rabbit mAb Research Reagent from ANT BIO PTE. LTD

ANT BIO PTE. LTD provides Phospho‑PLCγ1 (Tyr783) Recombinant Rabbit mAb (S0B0850), a phospho‑site‑specific antibody detecting activated PLCγ1 for T‑cell‑LLPS‑signalling, growth‑factor‑receptor‑biology and calcium‑mobilization‑oriented basic‑research assignments. Each antibody production lot undergoes phospho‑peptide‑array epitope‑specificity screening and multi‑assay functional‑validation prior to commercial‑product release.

Catalog Table of Phospho‑PLCγ1 (Tyr783) Research Antibody

Functional‑Validation Characteristics of ANT BIO PTE. LTD S0B0850 Antibody

S0B0850 selectively recognizes PLCγ1 phosphorylated Tyr783 activation‑loop epitope with minimal cross‑reactivity against unphosphorylated PLCγ1 polypeptide. Validated sample matrices include TCR‑stimulated T‑cell lysates, growth‑factor‑treated adherent‑cell extracts and fixed immune‑cell cytology specimens. Qualified experimental workflows include Western‑blot PLCγ1‑activation‑magnitude quantification and immunofluorescence intracellular‑localization imaging for co‑localization analysis versus LAT‑containing phase‑separated condensates. Recombinant‑antibody manufacturing delivers consistent lot‑to‑lot performance supporting repeatable signalling‑dynamic‑monitoring in adaptive‑immunology‑focused laboratory‑environments.

Core Fundamental‑Research Applications for Phospho‑PLCγ1 (Tyr783) Antibody

1. Western‑blot quantification of PLCγ1 Tyr783 phosphorylation time‑course profiles following TCR‑antigen‑stimulation in primary‑T‑cell experimental‑systems

2. Immunofluorescence‑based spatial‑co‑localization analysis of p‑PLCγ1 (Tyr783) together with LAT‑driven liquid‑liquid‑phase‑separated signalling condensates

3. Mechanistic‑research dissecting PLCγ1‑dependent LLPS‑modulation and CD45‑mediated de‑phosphorylation regulatory cascades in T‑cell‑receptor‑signal‑transduction

4. Pharmacodynamic biomarker read‑out assessing cellular response toward immunomodulatory small‑molecule compounds or CAR‑receptor construct variant comparative‑evaluation workflows

5. Comparative‑analysis of PLCγ1‑Tyr783 activation outputs downstream of RTK growth‑factor receptors, BCR‑Fc‑receptor and TCR antigen‑receptor stimulation‑conditions

6. Orthogonal signal‑validation paired with IP3‑DAG‑downstream effector detection for comprehensive multi‑read‑out evaluation of PLCγ1‑dependent signalling‑cascade activation‑states

Global Manufacturing & Compliance Standards

S0B0850 antibody batches complete phospho‑peptide‑array epitope‑specificity profiling and multi‑platform functional‑performance‑verification prior to commercial‑product release. Manufacturing facilities adhere to ISO9001, ISO13485 and EU 98/79/EC certification specifications governing life‑science‑research‑reagent‑production‑protocols. In‑house application‑science teams supply detailed immuno‑assay‑SOP documents and curated PLCγ1‑LLPS‑TCR‑signal‑transduction‑reference‑publication‑resources. The broader reagent ecosystem includes additional PTM‑detection antibodies, recombinant‑proteins and ELISA‑kits supporting comprehensive immunology‑cell‑biology multi‑omics‑research pipelines.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.